AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. on May 18, 2021, regarding an event occurring on that date. The Company is a Delaware corporation with its principal executive offices in Englewood, Colorado, and its common stock trades on The NASDAQ Stock Market LLC under the symbol "AYTU".
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the termination of a specific equity offering agreement.
Material Changes
The primary material change reported is the termination of an Open Market Sale Agreement (the "Sales Agreement") originally entered into on June 5, 2020, with Jefferies LLC. Under this agreement, the Company could sell up to $40 million of common stock through an "at the market" offering program. The Company delivered written notice to terminate the agreement effective June 2, 2021. Prior to termination, approximately $29.5 million of shares remained available for sale. The Company is not subject to any termination penalties.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the specific event of the agreement termination. No unusual items were reported.
Key Facts for Investor Verification
- Termination of the $40 million "at the market" equity offering program with Jefferies LLC.
- Effective date of termination is June 2, 2021.
- Approximately $29.5 million of shares were unsold at the time of termination.
- No termination penalties were incurred by the Company.
- The filing does not disclose the Company's current cash position or reasons for terminating the offering.